Cita APA (7th ed.)

Lundin, J., Kimby, E., Björkholm, M., Broliden, P., Celsing, F., Hjalmar, V., . . . Osterborg, A. (2002). Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Cita Chicago (17th ed.)

Lundin, J., et al. Phase II Trial of Subcutaneous Anti-CD52 Monoclonal Antibody Alemtuzumab (Campath-1H) as First-line Treatment for Patients with B-cell Chronic Lymphocytic Leukemia (B-CLL). 2002.

Cita MLA (9th ed.)

Lundin, J., et al. Phase II Trial of Subcutaneous Anti-CD52 Monoclonal Antibody Alemtuzumab (Campath-1H) as First-line Treatment for Patients with B-cell Chronic Lymphocytic Leukemia (B-CLL). 2002.